Expansion of the clinical and molecular spectrum of an XPD-related disorder linked to biallelic mutations in ERCC2 gene.


Journal

Clinical genetics
ISSN: 1399-0004
Titre abrégé: Clin Genet
Pays: Denmark
ID NLM: 0253664

Informations de publication

Date de publication:
06 2021
Historique:
revised: 05 03 2021
received: 17 11 2020
accepted: 10 03 2021
pubmed: 19 3 2021
medline: 19 2 2022
entrez: 18 3 2021
Statut: ppublish

Résumé

Bi-allelic inactivation of XPD protein, a nucleotide excision repair (NER) signaling pathway component encoded by ERCC2 gene, has been associated with several defective DNA repair phenotypes, including xeroderma pigmentosum, photosensitive trichothiodystrophy, and cerebro-oculo-facio-skeletal syndrome. We report a pediatric patient harboring two compound heterozygous variants in ERCC2 gene, c.361-1G>A and c.2125A>C (p.Thr709Pro), affected by severe postnatal growth deficiency, microcephaly, facial dysmorphisms and pilocytic astrocytoma of the brainstem. Some of these features point to a DNA repair syndrome, and altogether delineate a phenotype differentiating from disorders known to be associated with ERCC2 mutations. The DNA repair efficiency following UV irradiation in the proband's skin fibroblasts was defective indicating that the new set of ERCC2 alleles impacts on NER efficiency. Sequencing analysis on tumor DNA did not reveal any somatic deleterious point variant in cancer-related genes, while SNP-array analysis disclosed a 2 Mb microduplication involving the 7q34 region, spanning from KIAA1549 to BRAF, and resulting in the KIAA1549:BRAF fusion protein, a marker of pilocytic astrocytoma. In conclusion, this report expands the clinical and mutational spectrum of ERCC2-related disorders.

Identifiants

pubmed: 33733458
doi: 10.1111/cge.13957
doi:

Substances chimiques

DNA 9007-49-2
Xeroderma Pigmentosum Group D Protein EC 3.6.4.12
ERCC2 protein, human EC 5.99.-

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

842-848

Informations de copyright

© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Références

Hanawalt PC. Controlling the efficiency of excision repair. Mutat Res. 2001;485:3-13.
Lehmann AR. The xeroderma pigmentosum group D (XPD) gene: one gene, two functions, three diseases. Genes Dev. 2001;15:15-23.
Ferri D, Orioli D, Botta E. Heterogeneity and overlaps in nucleotide excision repair disorders. Clin Genet. 2020;97:12-24.
Jones DT, Gronych J, Lichter P, et al. MAPK pathway activation in pilocytic astrocytoma. Cell Mol Life Sci. 2012;69:1799-1811.
Jones DT, Kocialkowski S, Liu L, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 2008;68:8673-8677.
Taha H, Yehia M, Mahmoud M, et al. Incidence of kiaa1549-braf fusion gene in Egyptian pediatric low grade glioma. Clin Transl Med. 2015;3:4-10.
Botta E, Nardo T, Broughton BC, et al. Analysis of mutations in the XPD gene in Italian patients with trichothiodystrophy: site of mutation correlates with repair deficiency, but gene dosage appears to determine clinical severity. Am J Hum Genet. 1998;63:1036-1048.
Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803-820.
Gómez-Díaz B, Luz DELA, Ayala-Madrigal M, et al. Analysis of ERCC1 and ERCC2 gene variants in osteosarcoma, colorectal and breast cancer. Oncol Lett. 2015;9:1657-1661.

Auteurs

Emanuele Agolini (E)

Translational Cytogenomics Research Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Elena Botta (E)

Institute of Molecular Genetics LL Cavalli Sforza-CNR, Pavia, Italy.

Mariachiara Lodi (M)

Department of Hematology/Oncology, Gene and Cell Therapy, Bambino Gesù Children's Hospital, IRCSS, Rome, Italy.

Maria Cristina Digilio (MC)

Genetics and Rare Diseases Research Division, Bambino Gesù Children's Hospital, IRCSS, Rome, Italy.

Martina Rinelli (M)

Translational Cytogenomics Research Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Emanuele Bellacchio (E)

Genetics and Rare Diseases Research Division, Bambino Gesù Children's Hospital, IRCSS, Rome, Italy.

Viola Alesi (V)

Translational Cytogenomics Research Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Tiziana Nardo (T)

Institute of Molecular Genetics LL Cavalli Sforza-CNR, Pavia, Italy.

Giovanna Zambruno (G)

Genetics and Rare Diseases Research Division, Bambino Gesù Children's Hospital, IRCSS, Rome, Italy.

Donata Orioli (D)

Institute of Molecular Genetics LL Cavalli Sforza-CNR, Pavia, Italy.

Iside Alessi (I)

Department of Hematology/Oncology, Gene and Cell Therapy, Bambino Gesù Children's Hospital, IRCSS, Rome, Italy.

Luigi Boccuto (L)

College of Behavioral, Social and Health Sciences, Clemson University, Clemson, South Carolina, USA.
Greenwood Genetic Center, Greenwood, South Carolina, USA.

Sabrina Rossi (S)

Pathology Department, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Andrea Carai (A)

Neurosurgery Unit, Department of Neurosciences and Neurorehabilitation, Bambino Gesù Children's Hospital, IRCSS, Rome, Italy.

Giovanna Stefania Colafati (GS)

Neuroradiology Unit, Department of Imaging, Bambino Gesù Children's Hospital, IRCSS, Rome, Italy.

Antonella Cacchione (A)

Department of Hematology/Oncology, Gene and Cell Therapy, Bambino Gesù Children's Hospital, IRCSS, Rome, Italy.

Bruno Dallapiccola (B)

Genetics and Rare Diseases Research Division, Bambino Gesù Children's Hospital, IRCSS, Rome, Italy.

Antonio Novelli (A)

Translational Cytogenomics Research Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Angela Mastronuzzi (A)

Department of Hematology/Oncology, Gene and Cell Therapy, Bambino Gesù Children's Hospital, IRCSS, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH